Literature DB >> 15693056

SARS-CoV protease inhibitors design using virtual screening method from natural products libraries.

Bing Liu1, Jiaju Zhou.   

Abstract

Two natural products databases, the marine natural products database (MNPD) and the traditional Chinese medicines database (TCMD), were used to find novel structures of potent SARS-CoV protease inhibitors through virtual screening. Before the procedure, the databases were filtered by Lipinski's ROF and Xu's extension rules. The results were analyzed by statistic methods to eliminate the bias in target-based database screening toward higher molecular weight compounds for enhancing the hit rate. Eighteen lead compounds were recommended by the screening procedure. They were useful for experimental scientists in prioritizing drug candidates and studying the interaction mechanism. The binding mechanism was also analyzed between the best screening compound and the SARS protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693056      PMCID: PMC7166849          DOI: 10.1002/jcc.20186

Source DB:  PubMed          Journal:  J Comput Chem        ISSN: 0192-8651            Impact factor:   3.376


Introduction

Severe acute respiratory syndrome (SARS) is a serious epidemic disease dispersed in many countries during the period of the time from March to May 2003. In that extraordinary period, 5327 persons were infected, of whom 349 died (6.6%) in China (http://www.china.com.cn/chinese/zhuanti/feiyan/318261.htm). The main symptoms of SARS are hyperpyrexia, chilling, cough, and dyspnea. Confronted with this new human coronavirus, many scientists devoted themselves to related research. Marra1 and his coworkers discovered the genome sequence of the SARS‐associated coronavirus, which lit a lamp for the perplexed investigators. Based on Marra's work, Anand et al.2 built a main proteinase structure using the homology modeling approach. Jenwitheesuk3 indicated that existing HIV‐1 protease inhibitors have high binding affinity to the SARS coronavirus (SARS‐CoV) proteinase. His findings may help scientists to design SARS inhibitors. De Groot4 also believed that there were some similarities between SARS‐CoV and HIV. Xiong et al. found 73 available protease inhibitors from the MDDR database (MDL Drug Data Report, http://www.mdl.com/) by virtual screening.5 Lee et al.6 identified four potent compounds taken from 16 antiviral drugs in the NCI database [National Cancer Institute (NCI) Database (http://cactus.nci.nih.gov/ncidb2/)]. In a recent report, Sirois et al. screened 3.6 million compounds through virtual screening using the MOE software package.7 Wu et al.8 also contributed their excellent work by a cell‐based assay, and 15 compounds with potent anti‐SARS‐CoV activity were found, including two existing drugs. At present, there are still no effective SARS‐CoV protease inhibitors on the market, and the available ligand databases used for virtual screening are usually those of Western medicine databases, such as MDDR, NCI, ACD, etc. Traditional Chinese medicine has been playing an important role in China for thousands of years, and now it is an valuable source of complements in Western medicines. During the SARS‐spreading period, people in China used TCM to prevent the disease, with positive results. The prescriptions focus on Honeysuckle [Lonicera japonica, Caprifoliaceae], Indigowoad Root [Isatis indigotica, Cruciferae], Forsythia [Forsythia suspensa, Oleaceae], Swordlike Atractylodes [Atractylodes lancea, Compositae], Licorice [Glycyrrhiza uralensis, Leguminosae], etc. Along with the scale of isolating compounds from natural sources being bigger and bigger, many novel structures have been continually found. People are paying more attention to finding new effective drugs from natural sources, especially from medicinal plants and halobios. Unlike land‐dwelling living beings, owing to their unique habitat such as high salinity, very little light, and high pressure, the marine organisms have different metabolism routes. These facts result in remarkable structural diversity of marine natural products. It is the character that makes marine natural products an invaluable treasure. There are more than 12,000 new compounds that have been isolated from sea living beings, adding 500 to 800 new compounds each year.9, 10 A new antineoplastic drug, ET‐743, has been synthesized by PharmaMar.11 The compound originally was isolated from tunicates. It is undergoing its clinical test period II in both Europe and America, and is expected to come onto the market this year. In this article, we used two new natural products databases: the traditional Chinese medicines database (TCMD), and the marine natural products (MNPD), for virtual screening.

Database

Marine Natural Products Database

MNPD was constructed by our laboratory.12 There are 8078 compounds isolated from halobios, among them 3200 compounds are with bioactivity data, some 1200 with CAS Registry Numbers, and about 3700 with physical property data. This database runs on an ISIS/Base (MDL Information Systems, Inc.) platform.

Traditional Chinese Medicines Database

TCMD is a commercial database built by our laboratory (http://products.cambridgesoft.com/family.cfm?FID=57).13, 14, 15 It has 9127 entries. A typical entry includes detailed 3D molecular structures, English names and synonyms, physical properties, natural sources, and references information. Bioactivity data are available for 3000 of the entries. There are 3922 traditional Chinese medicine plant species including standard expression on TCM effects and indications. There are many antivirus and anti‐HIV compounds in TCMD. According to Jenwitheesuk and De Groot's findings, they are helpful in finding SARS‐CoV protease inhibitors.3, 4 Honeysuckle, Indigowoad Root, Forsythia, Swordlike Atractylodes, and Licorice are also important effective components of the anti‐SARS TCM prescription. TCMD is run on an ISIS/Base platform. All compound 2D structures in MNPD and TCMD were transformed to 3D molecules files by CONCORD standalone 4.016 at an SGI workstation.

Drug‐Like Filter

According to the Lipinski's Rule of Five (ROF), drug‐like compounds should have an appropriate molecular weight (MW), H‐bond donors, H‐bond acceptors, and LogP value.17 It has been difficult for molecules with larger molecular weight and lower LogP value to cross through the cell membrane. With larger LogP value, the drug will be difficult to dissolve in water, which is a necessary condition for drugs to be absorbed by an organism. Xu has extended that rule by definition of a drug‐like cluster center.18 The criteria we adopted here (see Table 1) for the filter of the two databases combined the ROF with Xu's regulations. Due to SARS‐CoV protease's larger active pocket, we expanded the MW to less than 900. Compounds with all their parameters meeting the drug‐like rules were picked out and written into a single molecules file. Then the databases were quickly narrowed to 3861 (MNPD) and 5454 (TCMD), respectively. LogP was calculated by the XLogP program.19
Table 1

Drug‐Like Filter Rules.

ParametersDrug‐like values
Number of H‐bond donors (HDN)0–5
Number of H‐bond acceptors (HAN)0–8
Number of aromatic bonds (AB)0–28
Number of smallest set of smallest rings (SSSRS)1–9
Average atomic numbers (AZ)6–10
Number of rotating bonds (RB)0–14
Average electronegativity (AE)2.55–3.02
Molecular weight (MW)≤900
Octanol–water partition coefficient (LogP) 0–5
Drug‐Like Filter Rules.

Virtual Screening Calculation

Virus Target

Rao20 and his coworkers reported a 1.90‐Å crystal structure of the SARS‐CoV protease (PDB entry code: 1UJ1). It is a dimer, and the active pocket located at protomer A, which contains three domains and the substrate‐binding site, is in a cleft between domain I and II (residues 8–101 and 102–184, respectively). The active site has a Cys–His catalytic dyad, which is composed of Cys145 and His41. Also, the substrate‐binding pocket consists of the side chains of His163 and Phe140, and the main‐chain atoms of Met165, Glu166, and His172.

Dock Parameters

The Dock4.02 package of the Linux version was used in the first step of the virtual screening procedure,21, 22 and computations were carried out in the cluster of the PC servers. Each computational node has an HP/Compaq DL360 industrial standard server with dual pentium III 1.13‐GHz CPUs and a 512‐kb L2 cache. Residues around the sulfur atom of Cys145 at a radius of 13 Å were isolated for constructing the grids of the docking screening. Energy scoring grids were obtained using an all‐atom model and a distance‐dependent dielectric function with a 10‐Å cutoff. The macromolecule was a loaded Kollman charge, with Gasteiger–Huckel charges for small molecules on the SYBYL6.8.23 An anchor fragment orientation method was performed, and 25 conformations were produced per cycle.

AutoDock Study

The top 200 candidates filtered by the Dock procedure in both databases were then studied by the AutoDock3.05 program, respectively. The computations were processed on an SGI Octane 2 graphics workstation. The grid has the space of 0.375 Å and a size of about 60 Å × 49 Å × 63 Å. The macromolecule and the small molecules were loaded on Kollman and Gasteiger‐Huckel charges, respectively, on the SYBYL6.8. The GA‐LS method was adopted using the default settings. Compounds with better AutoDock scores and binding conformations will be selected as lead compounds of SARS for next project.

Results and Discussion

Docking Data

Energy score (ES) is an important criterion to evaluate the binding affinity for the target protein with a ligand of certain orientation and conformation. With the shortcoming of scoring functions of the Dock program,24, 25, 26, 27, 28, 29, 30, 31, 32 the energy score is biased toward the selection of high molecular weight.33 Liu has provided a new arithmetic to eliminate this bias (unpublished data, Liu, Z. M; Shi, L; Lai, L. H. Considering Molecule Weight in Virtual Docking Screening: Implication for Inhibitors Selection). He found that most molecules with heavy atom number (HA) between 5 and 15 interact with the target protein in a proper binding mode. Those compounds usually represent the correct interacting mode of the whole data sets, whereas the energy scores of the molecules with a larger HA spread out partly because of more choices to escape from the “binding site” or pocket capacity limitation. HA numbers and the average energy scores have the relationship described as in eqs. (1) (MNPD) and (2) (TCMD). The HA–AE exponential decay fit curve of MNPD: The HA–AE exponential decay fit curve of TCMD: Figures 1 and 2 give the distribution curve of heavy atoms and energy scores.
Figure 1

Dock energy score distribution of MNPD. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Figure 2

Dock energy score distribution of TCMD. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Dock energy score distribution of MNPD. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.] Dock energy score distribution of TCMD. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Best Compounds In Silico

After repetitive evaluation of by AutoDock, 18 compounds of high affinity in silico were selected (7 from MNPD and 11 from TCMD). They will be useful for experimental scientists in prioritizing drug candidates and studying the interaction mechanism. These structures and their drug‐like parameters are listed in Table 2.
Table 2

Best 18 Compounds Found via Virtual Screening (Dock, kcal/mol; AutoDock, kcal/mol).

CompoundHANHDNABSSSRSAZRBAEMWLogP DockAutoDockStructure
M392733618.7972.76465.180.763−39.1−10.46
M4367451226.44122.75469.541.553−41.07−10.7
M489076636.48142.77642.753.42−44.24−11.76
M5410651226.49112.77512.561.464−41.71−11.21
M578973646.4972.77578.73.615−43.43−10.3
M660112619.6542.71370.133.39−36.23−9.67
M660235628.8852.8461.112.565−35.53−7.06
T143472646.4392.74580.672.83−37.54−12.36
T144162646.3992.72566.693.75−36.73−11.67
T282673676.3642.71575.711.83−39.20−11.21
T283173676.3832.72547.651.17−37.98−12.49
T4744422476.2432.66449.532.66−38.38−12.41
T53783646.38112.72623.792.16−39.57−12.11
T565682676.3552.71589.732.35−38.03−12.31
T6791531866.3882.72566.611.94−39.28−11.71
T8593532476.3322.7580.682.16−31.64−11.61
T309135626.5292.78434.492.571−37.51−6.91
T5242731246.3652.71575.711.52−31.78−12.51
Best 18 Compounds Found via Virtual Screening (Dock, kcal/mol; AutoDock, kcal/mol).

Conformation Analysis

The coronavirus family exhibits one main protease, called 3CL, because of the nature of the catalytic site that acts a crucial role in the regulation of the virus life‐cycle.2 Cys145 and His41 residues are considered to be essential for the normal function of SARS protein. The docking simulation of compound M4367, which was isolated from Pseudomonas sp. or Alteromonas sp. in sponge Dysidea fragilis (Black Sea), showed that the inhibitor is folded into a ring‐like structure in the active site that was similar with that of Wu's compound 2 (Wu‐2).8 The K value of Wu‐2 against the SARS‐CoV 3CL protease is 0.6 μm. One phenyl group of compound M4367 fits into the pocket defined by Leu27, Thr25, etc. One carbonyl instead of Wu‐2's phenyl fits into the pocket defined by the hydrophobic residues (Met165, Pro‐168, and Leu‐167). The M4367 groups interact with Cys145 and His41 directly by hydrogen bond interaction and hydrophobic contact. There are also four other hydrogen bonds between M4367 and Phe140, Ser144, Cys44, and Thr25, respectively. The complex was analyzed by the Ligplot 4.22 to identify some specific contacts (Fig. 3).34
Figure 3

Schematic representation of SARS–M4367 interactions. The ligand atoms serving as the correspondence points in the subsequent structural alignment processes were marked with the atom type beside it. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Schematic representation of SARSM4367 interactions. The ligand atoms serving as the correspondence points in the subsequent structural alignment processes were marked with the atom type beside it. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.] The SARS target was so novel that there are still no effective inhibitors available in the market. Marra1 reports that the derivatives of AG7088 might be good starting points for the design of anticoronavirus drugs. AG7088 has already been clinically tested for treatment of the common cold. Its docking complex with SARS‐CoV protease also has multiple interactions, which is similar to that of our recommended compounds (Fig. 4).
Figure 4

Schematic representation of the SARS–AG7088 interactions. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Schematic representation of the SARSAG7088 interactions. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Conclusion

Eighteen novel‐structure compounds with best binding affinities and conformations were found via virtual screening and statistic methods. The interaction and binding mechanism were elucidated by the complex structure of SARSM4367. The similarity of the protein binding mode between our screened compounds and Wu‐2, AG7088, which were reported as possible molecules of SARS inhibitors, showed certain values of our research for experimental scientists in prioritizing drug candidates. The results show that high‐affinity drugs for the SARS protein may have the characteristic of direct interaction with the functional residues, His41 and Cys145, which act as a crucial role in the regulation of the SARS life cycle.
  24 in total

1.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations.

Authors:  C Bissantz; G Folkers; D Rognan
Journal:  J Med Chem       Date:  2000-12-14       Impact factor: 7.446

Review 2.  Statistical potentials and scoring functions applied to protein-ligand binding.

Authors:  H Gohlke; G Klebe
Journal:  Curr Opin Struct Biol       Date:  2001-04       Impact factor: 6.809

3.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins.

Authors:  P S Charifson; J J Corkery; M A Murcko; W P Walters
Journal:  J Med Chem       Date:  1999-12-16       Impact factor: 7.446

4.  Small molecules targeting severe acute respiratory syndrome human coronavirus.

Authors:  Chung-Yi Wu; Jia-Tsrong Jan; Shiou-Hwa Ma; Chih-Jung Kuo; Hsueh-Fen Juan; Yih-Shyun E Cheng; Hsien-Hua Hsu; Hsuan-Cheng Huang; Douglass Wu; Ashraf Brik; Fu-Sen Liang; Rai-Shung Liu; Jim-Min Fang; Shui-Tein Chen; Po-Huang Liang; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

5.  Screening a peptidyl database for potential ligands to proteins with side-chain flexibility.

Authors:  V Schnecke; C A Swanson; E D Getzoff; J A Tainer; L A Kuhn
Journal:  Proteins       Date:  1998-10-01

6.  Concept design of computer-aided study on traditional Chinese drugs.

Authors:  X Yan; J Zhou; Z Xu
Journal:  J Chem Inf Comput Sci       Date:  1999 Jan-Feb

7.  Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.

Authors:  Kanchan Anand; John Ziebuhr; Parvesh Wadhwani; Jeroen R Mesters; Rolf Hilgenfeld
Journal:  Science       Date:  2003-05-13       Impact factor: 47.728

8.  The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor.

Authors:  Haitao Yang; Maojun Yang; Yi Ding; Yiwei Liu; Zhiyong Lou; Zhe Zhou; Lei Sun; Lijuan Mo; Sheng Ye; Hai Pang; George F Gao; Kanchan Anand; Mark Bartlam; Rolf Hilgenfeld; Zihe Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-29       Impact factor: 11.205

9.  Identifying inhibitors of the SARS coronavirus proteinase.

Authors:  Ekachai Jenwitheesuk; Ram Samudrala
Journal:  Bioorg Med Chem Lett       Date:  2003-11-17       Impact factor: 2.823

Review 10.  How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past.

Authors:  Anne S De Groot
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

View more
  16 in total

1.  Novel small-molecule inhibitors of transmissible gastroenteritis virus.

Authors:  Cheng-Wei Yang; Yung-Ning Yang; Po-Huang Liang; Chi-Min Chen; Wei-Liang Chen; Hwan-You Chang; Yu-Sheng Chao; Shiow-Ju Lee
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

Review 2.  Natural product-derived phytochemicals as potential agents against coronaviruses: A review.

Authors:  Janice S Mani; Joel B Johnson; Jason C Steel; Daniel A Broszczak; Paul M Neilsen; Kerry B Walsh; Mani Naiker
Journal:  Virus Res       Date:  2020-04-30       Impact factor: 3.303

3.  Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.

Authors:  Mahmoud Kandeel; Mohammed Al-Nazawi
Journal:  Life Sci       Date:  2020-04-03       Impact factor: 5.037

4.  A chemoinformatics approach to the discovery of lead-like molecules from marine and microbial sources en route to antitumor and antibiotic drugs.

Authors:  Florbela Pereira; Diogo A R S Latino; Susana P Gaudêncio
Journal:  Mar Drugs       Date:  2014-01-27       Impact factor: 5.118

Review 5.  The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?

Authors:  Andréa D Fuzimoto; Ciro Isidoro
Journal:  J Tradit Complement Med       Date:  2020-05-30

6.  In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.

Authors:  Deng-Hai Zhang; Kun-Lun Wu; Xue Zhang; Sheng-Qiong Deng; Bin Peng
Journal:  J Integr Med       Date:  2020-02-20

Review 7.  Virtual screening for the discovery of bioactive natural products.

Authors:  Judith M Rollinger; Hermann Stuppner; Thierry Langer
Journal:  Prog Drug Res       Date:  2008

Review 8.  A role for quercetin in coronavirus disease 2019 (COVID-19).

Authors:  Giuseppe Derosa; Pamela Maffioli; Angela D'Angelo; Francesco Di Pierro
Journal:  Phytother Res       Date:  2020-10-09       Impact factor: 6.388

Review 9.  Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus.

Authors:  Youssef A Attia; Mahmoud M Alagawany; Mayada R Farag; Fatmah M Alkhatib; Asmaa F Khafaga; Abdel-Moneim Eid Abdel-Moneim; Khalid A Asiry; Noura M Mesalam; Manal E Shafi; Mohammed A Al-Harthi; Mohamed E Abd El-Hack
Journal:  Front Vet Sci       Date:  2020-10-20

10.  Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.

Authors:  Marimuthu Ragavan Rameshkumar; Purushothaman Indu; Narasingam Arunagirinathan; Babu Venkatadri; Hamed A El-Serehy; Ajaz Ahmad
Journal:  Saudi J Biol Sci       Date:  2020-10-22       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.